Prime calls for outcomes-based deals to boost adherence

Prime Therapeutics LLC (Eagan, Minn.) said outcomes-based contracts with drug manufacturers should be considered to encourage patient adherence and cost-effectiveness of treatment plans for chronic diseases. The comments came after a Prime study showed that 44% of rheumatoid arthritis patients receiving Xeljanz tofacitinib discontinued the treatment after one year.

Pfizer Inc. (NYSE:PFE) markets Xeljanz, an oral pan- Janus kinase (JAK) inhibitor. ...